On July 9, 2024, theBeijing meeting of the "Rare Disease AI Diagnosis and Treatme♦ntCommittee" (hereinafter referred to as the AI Committee) under SMIA was held in the £Beijing conference room of the Cord Rare Disease Center.Attending the meeting were members oφf the SMIA Board of Directors, the AICommittee, the Cord Rare Disease Ce≠nter, Jatberlin, and the SMIA Secretariat.

The meeting began with introductions of their respectiveorganizations and collaboπration needs by the rotating Chairman of the AICommittee, Paul Li; D♣irector of the Cord Rare Disease Center, Huang Rufang;rotating Chairman of the SMI A Board, Lucky Geng; and Vice President ofCommercial Operations and General Manager< of Greater China at Jatberlin, ChenHaochang.

Subsequently, Mr. Lucky Geng, on behalf of the SMIA Boaαrd,presented Mr. Huang Rufang with a SMIA Vice Chairma∞n unit bronze plaqueand a Vice Chairman appointment letter. Mr→. Paul Li and Mr. Huang Rufang,on behalf of the AI Committee and SMIA Board resp≥ectively, presented Mr.Chen Haochang with an AI Committee Executive Chairman appointment letσter and aSMIA member unit appointment letter.

As a biotechnologycompany focused on providing innovative therapies for patients with rare and¶severe diseases, Jatberlin has been committed to working with various partnersto€ continuously support the development of China's healthcare industry through innovativedru g research and development, market access, disease education, and publicwelfare activities. L↑everaging the results brought by big data and AItechnology and₩ through digitalization efforts, Jatberlin strives to enhance$ itsability to serve patients and customers, which is& a key strategic measure insupporting the construction of the rare disease diagnosis and t♦reatment system.By joining the establishment of the Rare Dise↕ase AI Diagnosis and TreatmentCommittee, Jatberlin will leverage its unique advantages in the raβre diseaseand digitalization fields to provide greater support for the developmen t of therare disease cause in China.

During the workshopsession, the representatives discussed the v★alue, goals, and positioning of theAI Committee and confirmed the division of tasks and ®action plans among theparties, as follows:

1. Promote raredisease charity cycling activities

2. Advance theimplementation of the rare disease AI diagnosis and treatment projects in$target hospitals

3. Promote theTianzhu Free Trade Zone rare disease drug supply chain supervision★ platform

4. Facilitate theestablishment of the Greater Bay Area Pharmaceutical Se rvices InnovationPromotion Center

Finally, Chairman Lucky Geng summarized the meeting.×